CLEOCIN T Topical Solution, CLEOCIN T Topical Gel and CLEOCIN T Topical Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS ).
Apply a thin film of, CLEOCIN T Topical Lotion, CLEOCIN T Topical Gel, CLEOCIN T Topical Solution, or use a CLEOCIN T Topical Solution pledget for the application of CLEOCIN T twice daily to affected area. More than one pledget may be used. Each pledget should be used only once and then be discarded. CLEOCIN T Topical Solution is flammable. Avoid fire, flame, and smoking during and immediately following applicatio...
www.pfizer.comFor External Use
CLEOCIN T Topical Solution and CLEOCIN T Topical Lotion contain clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. CLEOCIN T Topical Gel contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram. Each CLEOCIN T Topical Solution pledget applicator contains approximately 1 mL of topical solution.
Clindamycin phosphate is a water soluble ester of the semi-synthetic antibacterial drug produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.
The solution contains isopropyl alcohol 50% v/v, propylene glycol, and water.
The gel contains allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water.
The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.
The structural formula is represented below:
The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate).
The mechanism of action of clindamycin in treating acne vulgaris is unknown.
Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0–3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.
Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.
Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.
Clindamycin is active in vitro against most isolates of Propionibacterium acnes; however, the clinical significance is unknown.
Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is complete. Because the binding sites for these antibacterial drugs overlap, cross-resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant bacteria.
CLEOCIN T Topical Solution, CLEOCIN T Topical Gel and CLEOCIN T Topical Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS, WARNINGS and ADVERSE REACTIONS).
CLEOCIN T Topical Solution, CLEOCIN T Topical Gel and CLEOCIN T Topical Lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.
Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in systemic absorption from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for Clostridioides difficile and stool assay for C. difficile toxin may be helpful diagnostically.
When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.
Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by Clostridioides difficile. The usual adult dosage is 500 milligrams to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days. Cholestyramine or colestipol resins bind vancomycin in vitro . If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.
Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.
CLEOCIN T Topical Solution contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), bathe with copious amounts of cool tap water. The solution has an unpleasant taste and caution should be exercised when applying medication around the mouth.
CLEOCIN T should be prescribed with caution in atopic individuals.
Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.
In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters has not been associated with an increased frequency of congenital abnormalities. There are no adequate studies in pregnant women during the first trimester of pregnancy. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.
It is not known whether clindamycin is excreted in breast milk following use of CLEOCIN T. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.
If used during lactation and CLEOCIN T is applied to the chest, care should be taken to avoid accidental ingestion by the infant.
Safety and effectiveness in pediatric patients under the age of 12 have not been established.
Clinical studies for CLEOCIN T did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In 18 clinical studies of various formulations of CLEOCIN T using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].
| Treatment Emergent Adverse Event | Solution n=553(%) | Gel n=148(%) | Lotion n=160(%) |
|---|---|---|---|
| # not recorded | |||
Burning | 62 (11) | 15 (10) | 17 (11) |
Itching | 36 ( 7) | 15 (10) | 17 (11) |
Burning/Itching | 60 (11) | # ( – ) | # ( – ) |
Dryness | 105 (19) | 34 (23) | 29 (18) |
Erythema | 86 (16) | 10 ( 7) | 22 (14) |
Oiliness/Oily Skin | 8 ( 1) | 26 (18) | 12* (10) |
Peeling | 61 (11) | # ( – ) | 11 ( 7) |
* of 126 subjects
Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.
Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).
Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin.
Topically applied CLEOCIN T can be absorbed in sufficient amounts to produce systemic effects (see WARNINGS).
Apply a thin film of, CLEOCIN T Topical Lotion, CLEOCIN T Topical Gel, CLEOCIN T Topical Solution, or use a CLEOCIN T Topical Solution pledget for the application of CLEOCIN T twice daily to affected area. More than one pledget may be used. Each pledget should be used only once and then be discarded.
CLEOCIN T Topical Solution is flammable. Avoid fire, flame, and smoking during and immediately following application.
Lotion: Shake well immediately before using.
Pledget: Remove pledget from foil just before use. Do not use if the seal is broken. Discard after single use.
Keep all liquid dosage forms in containers tightly closed.
CLEOCIN T Topical Solution containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following sizes:
30 mL applicator bottle—NDC 0009-3116-01
60 mL applicator bottle—NDC 0009-3116-02
Carton of 60 single-use pledget applicators—NDC 0009-3116-14
CLEOCIN T Topical Gel containing clindamycin phosphate equivalent to 10 mg clindamycin per gram is available in the following sizes:
60 gram tube—NDC 0009-3331-01
30 gram tube—NDC 0009-3331-02
CLEOCIN T Topical Lotion containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following size:
60 mL plastic squeeze bottle—NDC 0009-3329-01
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].
Protect from freezing.
CLEOCIN T Topical Solution is flammable. Keep away from heat, sparks or open flames.
Rx only
This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.
LAB-0042-11.0
Revised 11/2025
Pfizer
NDC 0009-3116-01
Cleocin T®
clindamycin phosphate
topical solution, USP
1%*
Solution for topical use only
30 mL
Rx only
Pfizer
NDC 0009-3116-01
Cleocin T®
clindamycin
phosphate
topical solution,
USP
1%*
Solution for topical
use only
30 mL
Rx only
Pfizer
NDC 0009-3116-14
Cleocin T®
clindamycin phosphate
topical solution, USP
1%*
Pledget for topical use only
1 Pledget
Distributed by
Pharmacia & Upjohn Co
Division of Pfizer Inc, NY, NY 10017
MADE IN CHINA
Rx only
NDC 0009-3116-14
Pfizer
Cleocin T®
1%*
clindamycin phosphate
topical solution, USP
Pledget for topical use only
60 Pledgets
Rx only
Pfizer
NDC 0009-3329-01
Cleocin T®
clindamycin
phosphate
topical lotion
1%*
For topical use only
60 mL
Rx only
Pfizer
NDC 0009-3329-01
Cleocin T®
clindamycin
phosphate
topical lotion
1%*
For topical use only
60 mL
Rx only
NDC 0009-3331-01
60 gram
Rx only
Cleocin T®
clindamycin phosphate topical gel
For topical use only
1%*
Store at controlled room temperature 20° to 25°C (68° to 77°F)
[see USP]. Protect from freezing.
For external use only. Avoid contact with eyes.
See crimp of tube for Expiration Date and Lot Number.
DOSAGE AND USE: See accompanying prescribing information.
* Each gram contains clindamycin phosphate equivalent to 10 mg
(1%) of clindamycin. Also contains allantoin, carbomer 934P,
methylparaben, polyethylene glycol 400, propylene glycol, sodium
hydroxide, and purified water.
Pfizer
Distributed by
Pharmacia & Upjohn Co
Division of Pfizer Inc, NY, NY 10017
NDC 0009-3331-01
Pfizer
Cleocin T®
1%*
clindamycin phosphate topical gel
For topical use only
60 gram
Rx only
NDC 0009-3331-02
30 gram
Rx only
Cleocin T®
clindamycin phosphate topical gel
For topical use only
1%*
Store at controlled room temperature 20° to 25°C (68° to 77°F)
[see USP]. Protect from freezing.
For external use only. Avoid contact with eyes.
See crimp of tube for Expiration Date and Lot Number.
DOSAGE AND USE: See accompanying prescribing information.
* Each gram contains clindamycin phosphate equivalent to 10 mg
(1%) of clindamycin. Also contains allantoin, carbomer 934P,
methylparaben, polyethylene glycol 400, propylene glycol, sodium
hydroxide, and purified water.
Pfizer
Distributed by
Pharmacia & Upjohn Co
Division of Pfizer Inc, NY, NY 10017
NDC 0009-3331-02
Pfizer
Cleocin T®
1%*
clindamycin phosphate topical gel
For topical use only
30 gram
Rx only
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 804975 | Cleocin T 1 % Topical Solution | PSN | 30 |
| 804978 | Cleocin T 1 % Twice-Daily Topical Gel | PSN | 30 |
| 804973 | Cleocin-T 1 % Topical Lotion | PSN | 30 |
| 197519 | clindamycin phosphate 1 % Topical Lotion | PSN | 30 |
| 309333 | clindamycin phosphate 1 % Topical Solution | PSN | 30 |
| 2676585 | clindamycin phosphate 1 % Twice-Daily Topical Gel | PSN | 30 |
| 804973 | clindamycin 10 MG/ML Topical Lotion [Cleocin-T] | SBD | 30 |
| 804975 | clindamycin 10 MG/ML Topical Solution [Cleocin-T] | SBD | 30 |
| 804978 | Twice-Daily clindamycin 0.01 MG/MG Topical Gel [Cleocin-T] | SBD | 30 |
| 197519 | clindamycin 10 MG/ML Topical Lotion | SCD | 30 |
| 309333 | clindamycin 10 MG/ML Topical Solution | SCD | 30 |
| 2676585 | Twice-Daily clindamycin 0.01 MG/MG Topical Gel | SCD | 30 |
| 804975 | Cleocin T Pledget 1 % Topical Solution | SY | 30 |
| 804978 | Cleocin-T (as clindamycin phosphate) 1 % Topical Gel | SY | 30 |
| 804973 | Cleocin-T (as clindamycin phosphate) 1 % Topical Lotion | SY | 30 |
| 804975 | Cleocin-T (as clindamycin phosphate) 1 % Topical Solution | SY | 30 |
| 804978 | Cleocin-T 0.01 MG/MG Topical Gel | SY | 30 |
| 804973 | Cleocin-T 1 % Topical Lotion | SY | 30 |
| 804975 | Cleocin-T 1 % Topical Solution | SY | 30 |
| 804978 | Cleocin-T 1 % Twice-Daily Topical Gel | SY | 30 |
| 804973 | Cleocin-T 10 MG/ML Topical Lotion | SY | 30 |
| 804975 | Cleocin-T 10 MG/ML Topical Solution | SY | 30 |
| 197519 | clindamycin (as clindamycin phosphate) 1 % Topical Lotion | SY | 30 |
| 309333 | clindamycin (as clindamycin phosphate) 1 % Topical Solution | SY | 30 |
| 2676585 | clindamycin (as clindamycin phosphate) 1 % Twice-Daily Topical Gel | SY | 30 |
| 197519 | clindamycin 1 % Topical Lotion | SY | 30 |
| 309333 | clindamycin 1 % Topical Solution | SY | 30 |
| 804978 | Twice-Daily Cleocin-T 0.01 MG/MG Topical Gel | SY | 30 |
| Class | Version | Type | Effective |
|---|---|---|---|
| CLINDAMYCIN Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20210811 |
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | DataBar Limited | (01)00300093329010 | GTIN-14: 00300093329010 GTIN-12: 300093329010 UPC-A: 300093329010 EAN-13: 0300093329010 GTIN storage (14 digits): 00300093329010 | cleocin-t-06.jpg |
| Barcode | DataBar Limited | (01)00300093331020 | GTIN-14: 00300093331020 GTIN-12: 300093331020 UPC-A: 300093331020 EAN-13: 0300093331020 GTIN storage (14 digits): 00300093331020 | cleocin-t-10.jpg |
| Barcode | EAN-13 | 0300093116016 | GTIN-13: 0300093116016 EAN-13: 0300093116016 GTIN-12: 300093116016 UPC-A: 300093116016 GTIN storage (14 digits): 00300093116016 | cleocin-t-04.jpg |
| Data code | Data Matrix | PAA077378 | cleocin-t-11.jpg | |
| Data code | Data Matrix | PAA097519 | cleocin-t-07.jpg |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0009-3116-01 | Cleocin T | 30 mL in 1 BOTTLE | SOLUTION | 30 | 30 | |
| 0009-3116-01 | Cleocin T | 1 in 1 CARTON | SOLUTION | 1 | 30 | |
| 0009-3116-02 | Cleocin T | 60 mL in 1 BOTTLE | SOLUTION | 60 | 30 | |
| 0009-3116-02 | Cleocin T | 1 in 1 CARTON | SOLUTION | 1 | 30 | |
| 0009-3116-14 | Cleocin T | 1 mL in 1 PACKET | SOLUTION | 1 | 30 | |
| 0009-3116-14 | Cleocin T | 60 in 1 CARTON | SOLUTION | 60 | 30 | |
| 0009-3329-01 | Cleocin T | 60 mL in 1 BOTTLE | LOTION | 60 | 30 | |
| 0009-3329-01 | Cleocin T | 1 in 1 CARTON | LOTION | 1 | 30 | |
| 0009-3331-01 | Cleocin T | 1 in 1 CARTON | GEL | 1 | 30 | |
| 0009-3331-01 | Cleocin T | 60 g in 1 TUBE | GEL | 60 | 30 | |
| 0009-3331-02 | Cleocin T | 30 g in 1 TUBE | GEL | 30 | 30 | |
| 0009-3331-02 | Cleocin T | 1 in 1 CARTON | GEL | 1 | 30 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0009-3116-01 | ML - Milliliter | 0009-3116 | 1eb9d45c-b035-4158-88b9-76f48fe60f79 | 1 | 2012-07-24 |
| 0009-3116-02 | ML - Milliliter | 0009-3116 | 24f4dfd7-2c75-4f7f-b3eb-0239fd137bb6 | 1 | 2012-07-24 |
| 0009-3116-14 | EA - Each | 0009-3116 | a906d567-2f88-4453-bc5c-6ea023f86daf | 1 | 2012-07-24 |
| 0009-3329-01 | ML - Milliliter | 0009-3329 | 060b71cd-b513-45e6-8c42-9b270af965c4 | 1 | 2012-07-24 |
| 0009-3331-01 | GM - Gram | 0009-3331 | e0145e85-dee3-40c9-a3a3-0b8b136a2a06 | 1 | 2012-07-24 |
| 0009-3331-02 | GM - Gram | 0009-3331 | 9ba379a8-b7b0-4ccc-a138-2635a833b705 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CLINDAMYCIN PHOSPHATE | ACTIVE INGREDIENT | EH6D7113I8 | 13 | |
| CLINDAMYCIN | ACTIVE MOIETY | 3U02EL437C | 13 | |
| ALLANTOIN | INACTIVE INGREDIENT | 344S277G0Z | 13 | |
| CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | INACTIVE INGREDIENT | HHT01ZNK31 | 13 | |
| CETOSTEARYL ALCOHOL | INACTIVE INGREDIENT | 2DMT128M1S | 13 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 13 | |
| ISOPROPYL ALCOHOL | INACTIVE INGREDIENT | ND2M416302 | 13 | |
| ISOSTEARYL ALCOHOL | INACTIVE INGREDIENT | Q613OCQ44Y | 13 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 13 | |
| POLYETHYLENE GLYCOL 400 | INACTIVE INGREDIENT | B697894SGQ | 13 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 13 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 13 | |
| SODIUM LAUROYL SARCOSINATE | INACTIVE INGREDIENT | 632GS99618 | 13 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 13 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 13 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0009-3116 | 0009-3116-01, 0009-3116-02, 0009-3116-14 |
| 0009-3329 | 0009-3329-01 |
| 0009-3331 | 0009-3331-01, 0009-3331-02 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SOLUTION / TOPICAL | 40 %w/v | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | LOTION / TOPICAL | 80 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | LOTION / TOPICAL | 3627 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | LOTION / TOPICAL | 5 %w/w | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | LOTION, AUGMENTED / TOPICAL | 2070 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LOTION / TOPICAL | 21 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | HHT01ZNK31 | LOTION / TOPICAL | 0.3 %w/w | ||
| CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | HHT01ZNK31 | LOTION / TOPICAL | 0.3 %w/w | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SPONGE / TOPICAL | 4 %w/w | ||
| ISOSTEARYL ALCOHOL | ISOSTEARYL ALCOHOL | Q613OCQ44Y | LOTION / TOPICAL | 100 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | OIL / TOPICAL | 72 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | GEL, METERED / TOPICAL | 525 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | GEL / TOPICAL | 75 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | GEL / TOPICAL | 75 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SPONGE / TOPICAL | 4 %w/w | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SWAB / TOPICAL | 43.9 %w/w | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | LOTION, AUGMENTED / TOPICAL | 2070 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | LOTION / TOPICAL | 21 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | GEL, METERED / TOPICAL | 525 mg | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | LOTION / TOPICAL | 3627 mg | ||
| SODIUM LAUROYL SARCOSINATE | SODIUM LAUROYL SARCOSINATE | 632GS99618 | LOTION / TOPICAL | 70 mg | ||
| ISOSTEARYL ALCOHOL | ISOSTEARYL ALCOHOL | Q613OCQ44Y | LOTION / TOPICAL | 100 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LOTION / TOPICAL | 3392 mg | ||
| SODIUM LAUROYL SARCOSINATE | SODIUM LAUROYL SARCOSINATE | 632GS99618 | LOTION / TOPICAL | 70 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | LOTION / TOPICAL | 3990 mg | ||
| ALLANTOIN | ALLANTOIN | 344S277G0Z | GEL / TOPICAL | 8 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | LOTION / TOPICAL | 80 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SWAB / TOPICAL | 43.9 %w/w | ||
| ALLANTOIN | ALLANTOIN | 344S277G0Z | GEL / TOPICAL | 8 mg | ||
| POLYETHYLENE GLYCOL 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | LOTION / TOPICAL | 5 %w/w | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | OIL / TOPICAL | 72 mg | ||
| ISOPROPYL ALCOHOL | ISOPROPYL ALCOHOL | ND2M416302 | SOLUTION / TOPICAL | 40 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N050537-001 | CLEOCIN T | CLINDAMYCIN PHOSPHATE | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | ||
| N050537-002 | CLEOCIN | CLINDAMYCIN PHOSPHATE | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SWAB / TOPICAL | RLD | 1994-02-22 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | c2088c7a36db… | ||
| 2026-10-15 13:18:30 | 2026-09 | N050537-002 | CLEOCIN | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SWAB / TOPICAL | RLD | 1994-02-22 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | N050537-002 | CLEOCIN | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SWAB / TOPICAL | RLD | 1994-02-22 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | N050537-002 | CLEOCIN | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SWAB / TOPICAL | RLD | 1994-02-22 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 301d65b070ca… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 1e350fbaab3a… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N050537-001 | CLEOCIN T | EQ 1% BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / TOPICAL | RLD, Approved before 1982 | 8072bd15b7f6… | ||
| 2024-05-31 18:47 UTC | 2024-05 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N050537-001 | CLEOCIN T | EQ 1% BASE | SOLUTION / TOPICAL | RLD, Approved before 1982 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N050537-001 | CLEOCIN T | EQ 1% BASE | SOLUTION / TOPICAL | RLD, Approved before 1982 | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N050537-001 | CLEOCIN T | EQ 1% BASE | SOLUTION / TOPICAL | RLD, Approved before 1982 | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N050537-002 | CLEOCIN | EQ 1% BASE | SWAB / TOPICAL | RLD | 1994-02-22 | 4b0b4de00fa7… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N050537-001 | AT | 1 | 74a2ff9319b5… |
| 2019-12-13 00:20 UTC | 2019-12 | N050537-002 | AT | 1 | 74a2ff9319b5… |
| 2021-03-12 10:30 UTC | 2021-03 | N050537-002 | AT | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N050537-001 | AT | 1 | 8869cabd3fbd… |
| 2020-12-22 03:56 UTC | 2020-12 | N050537-002 | AT | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N050537-001 | AT | 1 | c0c555d07b60… |
| 2020-11-12 02:37 UTC | 2020-11 | N050537-002 | AT | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N050537-001 | AT | 1 | 3f01610625f2… |
| 2019-12-14 00:12 UTC | 2019-12 | N050537-002 | AT | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N050537-001 | AT | 1 | b00525d2431f… |
| 2019-09-15 20:21 UTC | 2019-09 | N050537-002 | AT | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N050537-001 | AT | 1 | ea99ee380514… |
| 2019-07-19 19:46 UTC | 2019-07 | N050537-002 | AT | 1 | ea99ee380514… |
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N050600-001 | CLEOCIN T | CLINDAMYCIN PHOSPHATE | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 |
| Application-product | TE code |
|---|---|
| N050600-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050600-001 | CLEOCIN T | EQ 1% BASE | LOTION / TOPICAL | AB | RLD, RS | 1989-05-31 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N050600-001 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N050600-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N050600-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N050600-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N050600-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N050600-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N050600-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N050600-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N050600-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N050600-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N050600-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N050600-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N050600-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N050600-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N050600-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N050600-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N050600-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N050600-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N050600-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N050600-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N050600-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N050600-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N050600-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N050600-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N050600-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N050600-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N050600-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N050600-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N050600-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N050600-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N050600-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N050600-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N050600-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N050600-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N050600-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N050600-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N050600-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N050600-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N050600-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050600-001 | AB | 1 | 3a93d1ddd44b… |
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N050615-001 | CLEOCIN T | CLINDAMYCIN PHOSPHATE | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 |
| Application-product | TE code |
|---|---|
| N050615-001 | AB1 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB | RLD, RS | 1987-01-07 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050615-001 | CLEOCIN T | EQ 1% BASE | GEL / TOPICAL | AB1 | RLD, RS | 1987-01-07 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | N050615-001 | AB1 | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | N050615-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N050615-001 | AB1 | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N050615-001 | AB1 | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N050615-001 | AB1 | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N050615-001 | AB1 | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N050615-001 | AB1 | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N050615-001 | AB1 | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N050615-001 | AB1 | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N050615-001 | AB1 | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N050615-001 | AB1 | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N050615-001 | AB1 | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N050615-001 | AB1 | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N050615-001 | AB1 | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N050615-001 | AB1 | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N050615-001 | AB1 | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N050615-001 | AB1 | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N050615-001 | AB1 | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N050615-001 | AB1 | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N050615-001 | AB1 | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N050615-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N050615-001 | AB1 | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N050615-001 | AB1 | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N050615-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N050615-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N050615-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N050615-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N050615-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N050615-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N050615-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N050615-001 | AB1 | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N050615-001 | AB1 | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N050615-001 | AB1 | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N050615-001 | AB1 | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N050615-001 | AB1 | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N050615-001 | AB1 | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N050615-001 | AB1 | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N050615-001 | AB1 | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N050615-001 | AB1 | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N050615-001 | AB1 | 1 | 3a93d1ddd44b… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cleocin T | CLINDAMYCIN PHOSPHATE | Pharmacia & Upjohn Company LLC | 4a3901a4-194f-4a15-9c85-3d0982afcf31 | 2025-11-24 | Warnings, Adverse reactions | 0009-3329-01 0009-3116-14 0009-3331-01 0009-3116-02 0009-3331-02 0009-3116-01 0009-3331 0009-3329 0009-3116 00009333101 00009311602 00009332901 00009311601 00009311614 00009333102 469e01f2-6431-4cee-8e1d-073fe187f87d 4a3901a4-194f-4a15-9c85-3d0982afcf31 |
Adverse event summaries are temporarily unavailable. Other product information remains available.